Equities

Nippon Shinyaku Co Ltd

Nippon Shinyaku Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)3,389.00
  • Today's Change38.00 / 1.13%
  • Shares traded254.20k
  • 1 Year change-49.01%
  • Beta0.6192
Data delayed at least 20 minutes, as of Sep 19 2024 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Nippon Shinyaku Co., Ltd. is a Japan-based company principally involved in the manufacture and sale of pharmaceutical products and functional foodstuffs. The Company operates in two business segments. The Pharmaceutical segment is involved in the manufacture and sale of urinary system therapeutic agents, blood cancer therapeutic agents, pain, inflammation and allergic therapeutic agents, digestive system therapeutic agents, cardiovascular systems and metabolic therapeutic agents. The Functional Foodstuff segment involves in the manufacture and sale of health food materials, quality stability preservatives, protein preparation, spice and seasoning products. The Company is also involved in the business support business, non-life insurance agency business, as well as the provision of real estate leasing services.

  • Revenue in JPY (TTM)150.37bn
  • Net income in JPY27.37bn
  • Incorporated1919
  • Employees2.21k
  • Location
    Nippon Shinyaku Co Ltd14, Nishinosho Monguchi-cho,Kisshoin, Minami-kuKYOTO-SHI 601-8550JapanJPN
  • Phone+81 753211111
  • Fax+81 753210678
  • Websitehttps://www.nippon-shinyaku.co.jp/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Zeria Pharmaceutical Co Ltd78.88bn9.03bn118.83bn1.78k10.921.207.081.51204.82204.821,789.401,858.720.54181.503.7144,387,400.006.203.899.826.2873.2271.9311.447.570.8393--0.350835.0910.744.1424.7817.4920.775.29
Mochida Pharmaceutical Co Ltd103.55bn4.41bn121.03bn1.52k26.060.898816.621.17123.93123.932,908.723,593.560.65651.753.4268,032,190.002.804.373.345.3150.0552.474.266.713.31--0.0045.16-0.3641-1.26-31.61-11.6310.91-1.21
Towa Pharmaceutical Co Ltd235.95bn16.92bn152.38bn4.59k8.610.89334.320.6458343.72343.724,793.823,311.490.55821.493.6051,428,070.004.004.214.915.6335.9039.237.177.231.62--0.566621.019.1316.74634.803.7228.2010.86
Kissei Pharmaceutical Co Ltd77.43bn12.00bn172.10bn1.78k13.000.701910.482.22268.51268.511,728.184,972.530.32041.552.9043,524,450.005.003.615.383.9049.9049.4715.5912.694.93--0.00634.8711.980.89196.0015.286.5810.40
KAKEN PHARMACEUTICAL CO., LTD.72.15bn7.27bn179.85bn1.14k20.381.0417.922.49192.09192.091,906.843,763.430.4221.983.2363,566,520.004.256.834.887.8753.4154.7810.0814.483.98--0.026351.25-1.29-5.2147.52-14.700.36390.00
Sumitomo Pharma Co Ltd329.55bn-260.17bn229.59bn4.98k--1.43--0.6967-654.85-654.85829.49404.890.3281.203.8866,174,100.00-25.89-5.07-45.34-7.7360.2269.99-78.94-12.280.419--0.7079---43.38-7.29-322.71--4.02--
Nippon Shinyaku Co., Ltd.150.37bn27.37bn235.41bn2.21k8.250.99367.221.57406.30406.302,232.623,372.500.59761.373.2067,949,390.0010.8810.4512.4112.3166.8161.2718.2016.473.73--0.011432.622.835.2613.329.6645.9312.12
Sawai Group Holdings Co Ltd178.04bn17.78bn266.44bn3.48k15.011.258.821.50404.94584.994,058.784,883.080.46711.172.8351,130,670.003.480.71044.620.970531.1435.087.441.471.5843.190.292788.138.04-0.824946.82-2.3318.150.00
Tsumura & Co157.50bn23.56bn299.05bn4.14k12.561.058.291.90310.18310.182,073.963,712.370.37030.70432.2938,061,620.005.904.817.395.8947.5950.9815.9412.652.31--0.205832.167.714.521.372.7417.545.84
Hisamitsu Pharmaceutical Co Inc145.42bn14.71bn332.99bn2.76k20.291.0816.122.29192.71192.711,905.693,607.430.44133.013.6152,707,500.004.624.225.504.8255.7458.6210.4710.033.09--0.004253.0510.42-0.238518.97-6.1728.900.5989
Data as of Sep 19 2024. Currency figures normalised to Nippon Shinyaku Co Ltd's reporting currency: Japanese Yen JPY

Institutional shareholders

16.72%Per cent of shares held by top holders
HolderShares% Held
Nomura Asset Management Co., Ltd.as of 29 Feb 20243.10m4.42%
The Vanguard Group, Inc.as of 04 Sep 20241.76m2.51%
FIL Investments (Japan) Ltd.as of 30 Apr 20241.14m1.63%
BlackRock Fund Advisorsas of 31 Aug 20231.14m1.62%
Norges Bank Investment Managementas of 31 Dec 20231.01m1.44%
BlackRock Japan Co. Ltd.as of 31 Aug 2023931.80k1.33%
Nikko Asset Management Co., Ltd.as of 06 Sep 2024825.50k1.18%
Daiwa Asset Management Co. Ltd.as of 30 Aug 2024782.20k1.11%
Dimensional Fund Advisors LPas of 05 Sep 2024547.29k0.78%
Sumitomo Mitsui DS Asset Management Co., Ltd.as of 05 Sep 2024498.60k0.71%
More ▼
Data from 30 Jun 2024 - 31 Jul 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.